---
document_datetime: 2025-11-23 08:04:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-mylan.html
document_name: ribavirin-mylan.html
version: success
processing_time: 0.1057895
conversion_datetime: 2025-12-27 23:16:18.598298
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ribavirin Mylan (previously Ribavirin Three Rivers)

[RSS](/en/individual-human-medicine.xml/66374)

##### Withdrawn

This medicine's authorisation has been withdrawn

ribavirin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 27 October 2020, the European Commission withdrew the marketing authorisation for Ribavirin Mylan (ribavirin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mylan S.A.S, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Ribavirin Mylan was granted marketing authorisation in the EU on 10 June 2010 for treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2015. The product had not been marketed in the EU since June 2018.

Ribavirin Mylan is a generic medicine of Rebetol. There are other generic medicinal products of Rebetol authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Ribavirin Mylan is updated to indicate that the marketing authorisation is no longer valid.

Ribavirin Mylan: EPAR - Summary for the public

English (EN) (638.44 KB - PDF)

**First published:** 02/07/2010

**Last updated:** 17/02/2011

[View](/en/documents/overview/ribavirin-mylan-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-844)

български (BG) (788.33 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/bg/documents/overview/ribavirin-mylan-epar-summary-public_bg.pdf)

español (ES) (707.38 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/es/documents/overview/ribavirin-mylan-epar-summary-public_es.pdf)

čeština (CS) (761.42 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/cs/documents/overview/ribavirin-mylan-epar-summary-public_cs.pdf)

dansk (DA) (701.26 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/da/documents/overview/ribavirin-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (706.79 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/de/documents/overview/ribavirin-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (701.44 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/et/documents/overview/ribavirin-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (820.61 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/el/documents/overview/ribavirin-mylan-epar-summary-public_el.pdf)

français (FR) (702.79 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/fr/documents/overview/ribavirin-mylan-epar-summary-public_fr.pdf)

italiano (IT) (704.38 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/it/documents/overview/ribavirin-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (764.33 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/lv/documents/overview/ribavirin-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (727.21 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/lt/documents/overview/ribavirin-mylan-epar-summary-public_lt.pdf)

magyar (HU) (775.44 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/hu/documents/overview/ribavirin-mylan-epar-summary-public_hu.pdf)

Malti (MT) (703.48 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/mt/documents/overview/ribavirin-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (705.09 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/nl/documents/overview/ribavirin-mylan-epar-summary-public_nl.pdf)

polski (PL) (781.57 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/pl/documents/overview/ribavirin-mylan-epar-summary-public_pl.pdf)

português (PT) (704.71 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/pt/documents/overview/ribavirin-mylan-epar-summary-public_pt.pdf)

română (RO) (727.77 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/ro/documents/overview/ribavirin-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (759.44 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/sk/documents/overview/ribavirin-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (755.09 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/sl/documents/overview/ribavirin-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (701.09 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/fi/documents/overview/ribavirin-mylan-epar-summary-public_fi.pdf)

svenska (SV) (638.17 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

17/02/2011

[View](/sv/documents/overview/ribavirin-mylan-epar-summary-public_sv.pdf)

## Product information

Ribavirin Mylan : EPAR - Product Information

English (EN) (1.12 MB - PDF)

**First published:** 02/07/2010

**Last updated:** 31/07/2019

[View](/en/documents/product-information/ribavirin-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-499)

български (BG) (3.3 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/bg/documents/product-information/ribavirin-mylan-epar-product-information_bg.pdf)

español (ES) (1.72 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/es/documents/product-information/ribavirin-mylan-epar-product-information_es.pdf)

čeština (CS) (2.64 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/cs/documents/product-information/ribavirin-mylan-epar-product-information_cs.pdf)

dansk (DA) (1.71 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/da/documents/product-information/ribavirin-mylan-epar-product-information_da.pdf)

Deutsch (DE) (1.77 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/de/documents/product-information/ribavirin-mylan-epar-product-information_de.pdf)

eesti keel (ET) (2.01 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/et/documents/product-information/ribavirin-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (3.39 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/el/documents/product-information/ribavirin-mylan-epar-product-information_el.pdf)

français (FR) (1.74 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/fr/documents/product-information/ribavirin-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (1.8 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/hr/documents/product-information/ribavirin-mylan-epar-product-information_hr.pdf)

íslenska (IS) (1.69 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/is/documents/product-information/ribavirin-mylan-epar-product-information_is.pdf)

italiano (IT) (1.7 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/it/documents/product-information/ribavirin-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (2.77 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/lv/documents/product-information/ribavirin-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.76 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/lt/documents/product-information/ribavirin-mylan-epar-product-information_lt.pdf)

magyar (HU) (2.63 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/hu/documents/product-information/ribavirin-mylan-epar-product-information_hu.pdf)

Malti (MT) (2.82 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/mt/documents/product-information/ribavirin-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (1.66 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/nl/documents/product-information/ribavirin-mylan-epar-product-information_nl.pdf)

norsk (NO) (1.63 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/no/documents/product-information/ribavirin-mylan-epar-product-information_no.pdf)

polski (PL) (2.77 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/pl/documents/product-information/ribavirin-mylan-epar-product-information_pl.pdf)

português (PT) (1.68 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/pt/documents/product-information/ribavirin-mylan-epar-product-information_pt.pdf)

română (RO) (1.81 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/ro/documents/product-information/ribavirin-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (2.65 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/sk/documents/product-information/ribavirin-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (2.61 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/sl/documents/product-information/ribavirin-mylan-epar-product-information_sl.pdf)

Suomi (FI) (1.76 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/fi/documents/product-information/ribavirin-mylan-epar-product-information_fi.pdf)

svenska (SV) (1.55 MB - PDF)

**First published:**

02/07/2010

**Last updated:**

31/07/2019

[View](/sv/documents/product-information/ribavirin-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0030 13/03/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ribavirin Mylan : EPAR - All Authorised presentations

English (EN) (597.59 KB - PDF)

**First published:** 02/07/2010

**Last updated:** 04/09/2012

[View](/en/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-620)

български (BG) (666.79 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/bg/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (607.88 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/es/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (656.36 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/cs/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (606.67 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/da/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (607.21 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/de/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (607.19 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/et/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (663.93 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/el/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (610.37 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/fr/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (608.03 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/is/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (606.55 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/it/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (657.85 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/lv/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (649.53 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/lt/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (682.07 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/hu/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (650.63 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/mt/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (613.38 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/nl/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (606.36 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/no/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (653.1 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/pl/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (606.66 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/pt/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (638.22 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/ro/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (655.76 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/sk/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (635.32 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/sl/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (615.06 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/fi/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (606.44 KB - PDF)

**First published:**

02/07/2010

**Last updated:**

04/09/2012

[View](/sv/documents/all-authorised-presentations/ribavirin-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ribavirin Mylan (previously Ribavirin Three Rivers) Active substance ribavirin International non-proprietary name (INN) or common name ribavirin Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AB04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.

There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).

Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.

**Naïve patients**

*Adult patients*

Ribavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.

*Children and adolescents*

Ribavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).

**Previously treatment-failure patients**

*Adult patients*

Ribavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.

## Authorisation details

EMA product number EMEA/H/C/001185

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan S.A.S

117 Allee des Parcs

Marketing authorisation issued 10/06/2010 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ribavirin Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (797.34 KB - PDF)

**First published:** 17/02/2011

**Last updated:** 31/07/2019

[View](/en/documents/procedural-steps-after/ribavirin-mylan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Ribavirin Mylan-H-C-1185-PSUSA-10007-201307 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/318854/2014

English (EN) (638.91 KB - PDF)

**First published:** 19/06/2014

**Last updated:** 19/06/2014

[View](/en/documents/scientific-conclusion/ribavirin-mylan-h-c-1185-psusa-10007-201307-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ribavirin Three Rivers : EPAR - Public assessment report

English (EN) (946.24 KB - PDF)

**First published:** 02/07/2010

**Last updated:** 02/07/2010

[View](/en/documents/assessment-report/ribavirin-three-rivers-epar-public-assessment-report_en.pdf)

CHMP positive summary of opinion for Ribavirin Three Rivers

Adopted

Reference Number: EMA/CHMP/143985/2010

English (EN) (626.37 KB - PDF)

**First published:** 19/03/2010

**Last updated:** 19/03/2010

[View](/en/documents/smop-initial/chmp-positive-summary-opinion-ribavirin-three-rivers_en.pdf)

**This page was last updated on** 23/11/2020

## Share this page

[Back to top](#main-content)